Can routine laboratory data guide empirical prescribing? by Ludlam, H et al.
Abubakar, I; Kanka, D; Arch, B; Porter, J; Weissberg, P (2004) Out-
come after acute myocardial infarction: a comparison of patients seen
by cardiologists and general physicians. BMC Cardiovasc Disord, 4.
p. 14. ISSN 1471-2261
Downloaded from: http://researchonline.lshtm.ac.uk/454/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cardiovascular Disorders
Open Access Research article
Outcome after acute myocardial infarction: a comparison of 
patients seen by cardiologists and general physicians
Ibrahim Abubakar*1,2, David Kanka3, Barbara Arch4, Jo Porter5 and 
Peter Weissberg6
Address: 1School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ UK, 2Health Protection Agency Regional 
Epidemiology Unit (East of England), Institute of Public Health, Cambridge CB2 2SR, UK, 3Director of Public Health, South Cambridgeshire 
Primary Care Trust, Heron Court, Cambridge, UK, 4CAMS, Institute of Public Health, Cambridge, UK, 5Department of Cardiology, Peterborough 
District Hospital, Peterborough, UK and 6Department of Cardiology, Addenbrooke's Hospital, Cambridge, UK
Email: Ibrahim Abubakar* - ibrahim.abubakar@hpa.org.uk; David Kanka - david.kanka@southcambs-pct.nhs.uk; 
Barbara Arch - barbara.arch@dunelm.org.uk; Jo Porter - elaine.thurston@pbh-tr.nhs.uk; Peter Weissberg - plw@mole.bio.cam.ac.uk
* Corresponding author    
Abstract
Background: The management of acute myocardial infarction (AMI) has improved over the last
50 years with the more frequent use of effective medicines and procedures. The clinical benefit of
the speciality of the attending physician is less clear. The United Kingdom National Service
Framework for coronary heart disease (CHD) suggested that patients with CHD are likely to
benefit from cardiological supervision. We set out to assess the effect of access to cardiologists on
survival among AMI patients admitted in two UK hospitals.
Methods: The study was conducted in a university hospital and a district general hospital in
England. Information was obtained on age, sex, ethnicity, Carstairs socioeconomic deprivation
category derived from postcode of residence, comorbidity, distance from hospital and medication
from all patients admitted with acute myocardial infarction in two acute trusts between July 1999
and June 2000. Record linkage to subsequent Hospital Episode Statistics and Registrar General's
death records provided follow up information on procedures and mortality up to eighteen months
after admission. Cox proportional hazard models were used to investigate the main hypothesis
controlling for confounding. The main outcome measure was 18-month survival after myocardial
infarction.
Results: Access to a cardiologist was univariately associated with improved survival (hazard ratio
0.16, 95% CI 0.10 to 0.25). This effect remained after controlling for the effect of patient
characteristics (hazard ratio 0.22, 95% CI 0.14 to 0.25). The effect disappeared after controlling for
access to effective medication (hazard ratio 0.70, 95% CI 0.33 to 1.46).
Conclusions: Access to a cardiologist is associated with better survival compared to no access to
a cardiologist among a cohort of patients already admitted with AMI. This effect is mainly due to
the more frequent use of effective medicines by the group referred to cardiologists. Hospitals may
improve survival by improving access to effective medicines and by coordinating care between
cardiologists and general physicians.
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Background
The management of acute myocardial infarction (AMI)
has improved over the last 50 years with the more fre-
quent use of effective medicines and procedures. The clin-
ical benefit of the speciality of the attending physician is
less clear. The effect of the speciality of the attending phy-
sician on mortality in AMI has been studied mainly in the
United States (US) with conflicting results arising from
the studies [3-6]. The explanations considered for the dif-
ference in mortality observed in some of the studies
include patient's condition (case mix and comorbid-
ity)[3], volume of workload[5,7] and treatment given[3].
Previous studies show that knowledge and use of effective
medicines is better among cardiologists compared with
general physicians in the US [8-10]. Co-ordination of care
between cardiologists and non-cardiologists also
improves survival of patients seen by non-cardiologists
[11].
The National Service Framework (NSF) for coronary heart
disease (CHD) published in March 2000, suggested that
patients with CHD are likely to benefit from cardiological
supervision. To provide this level of care, all acute hospi-
tals will eventually need a minimum of two cardiologists
[1]. A recent survey by the Royal College of Physicians
found an average of 1.7 whole time equivalent (WTE) car-
diologists in the 211 hospitals receiving patients with AMI
in the UK [2]. Eight hospitals did not have a cardiologist.
There is a need to establish whether the involvement of a
cardiologist in the management of AMI patients affects
the quality and outcome of care, and if so to identify ways
to improve the outcome of care for patients unable to gain
access to a cardiologist. This study aims to assess the effect
of access to cardiologists on survival among AMI patients
accounting for access to effective investigation, medica-
tion, procedures and the underlying condition of the
patient at presentation.
Methods
A retrospective cohort design was used.
Study population and inclusion criteria
All patients admitted to two hospitals in Eastern England
between 1st July 1999 and 31st June 2000 with a discharge
diagnosis of AMI were included in the analysis. A diagno-
sis of AMI was based on evidence of raised cardiac
enzymes and/or other indicators of myocardial necrosis
and on a physician's judgement of ECG changes indicative
of AMI.
Data collection and analysis
Hospital Episode Statistics were used to extract records of
all patients admitted with the ICD10 diagnostic codes for
Acute Myocardial Infarction (I21, I22, I23) in any diag-
nostic field. The records were restructured to produce one
record per patient using the new NHS number. For
records with missing NHS number, a unique identifier
was created using date of birth, sex and post code. The
unique identifier was also used as a check for the records
with NHS numbers. Records of all Finished Consultant
Episodes with OPCS 4 codes of either Coronary Artery
Bypass Grafting (K40–46) or Percutaneous Transluminal
Coronary Angiography (K49–50) were extracted. The
process was repeated for angiography (K63 – 65). Record
linkage with subsequent Hospital Episode Statistics and
Registrar General's records provided follow up informa-
tion on procedures and death up to eighteen months after
the index AMI.
All cases were reviewed by examining the case notes.
Detailed information on variables summarised below was
obtained.
List of variables extracted from patients' case notes
• Hospital where patient was first admitted
• Whether the patient was seen by a cardiologist or not,
determined by evidence of a cardiology review in a
patients case note
• The average distance from residence to hospital first seen
was determined by mapping the distance in miles using
the RAC™ website distance calculator
• A history of comorbidity – defined as the presence of
diabetes, metastatic malignancy, cerebrovascular accident
(CVA), asthma, chronic obstructive airway disease, renal
impairment, endocrine disorder, chronic infection,
dementia
• Physical impairment with poor mobility
• Procedures – exercise testing, angiography, CABG, PTCA
• Appropriate medication – β blockers, aspirin, ACE
inhibitors, thrombolysis (table 2)
• A history of
 Smoking
 Previous MI
 Hypertension
• Impaired left ventricular function based on echocardiog-
raphy result or angiography
¾
¾
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• Severity of AMI using the number of vessels affected
(vessels were considered affected if a lesion of 50% or
more was noted in the angiography report)
• Demographic factors: age, sex, ethnicity, socioeconomic
status and Carstairs socio-economic deprivation category
derived from postcode of residence
Baseline patient characteristics were tabulated. Categori-
cal variables were tested for statistical significance using
the χ2 test. Continuous variables were tested using the Stu-
dent t test comparing patients seen by cardiologists and
those seen by other physicians.
The relative odds of drug and procedure use by speciality
of physician were calculated. Specific variables included
the use of thrombolytic therapy, β blockers, aspirin, ACE
inhibitors among clinically appropriate groups, and the
use of exercise testing, coronary angiography, angioplasty
and coronary artery bypass grafting (CABG).
Cox proportional hazards models were used to investigate
the effect on survival of seeing a cardiologist. Multivariate
models were fitted to control for the effect of patient and
hospital characteristics. Controlled factors included: age,
sex, comorbidity, hospital, distance from patients resi-
dence to hospital and Carstairs socio-economic depriva-
tion category in the first instance. The effect of
angiography, revascularisation and the use of effective
medicines (aspirin and/or β blockers and/or thrombolysis
– eligibility criteria listed below) were subsequently intro-
duced into the model to investigate whether these affected
outcome. The factors were included in the model either
because they are known to confound the association
Table 1: Patient characteristics, and whether seen by cardiologist or by general physician
Patient characteristic Physician
Cardiologist (N = 275) Non Cardiologist (N = 201)
Mean age (SD) 64.4 (SD 12.8) 74.8 (SD 11.4)
Sex n (%) Male 275 (71.4) 201 (52.8)
History of:
Congestive heart failure % 11.3 29.6
Angina % 94.9 86.7
Hypertension % 41.8 46.6
Diabetes mellitus % 12.1 17.1
Impaired mobility % 7.8 17.7
Smoking % 36.0 49.6
Impaired left ventricular function % 24.6 25.0
Table 2: Odds ratios for drug and procedure use after AMI by physician (cardiologist relative to non-cardiologist)
Intervention Number (Percent) Odds ratio (95% CI)
Cardiologist (275) Non Cardiologist (201)
Thrombolytic therapy* 140 (51%) 66 (33%) 2.08 (1.35 – 3.23)
β blocker on discharge* 206 (75%) 90 (45%) 3.70 (2.38 – 5.56)
Aspirin* 264 (96%) 160 (80%) 6.67 (3.23 – 14.29)
ACE inhibitors 124 (45%) 80 (40%) 1.27 (0.01 – 1.92)
Exercise testing 192 (70%) 46 (23%) 7.70 (4.76 – 12.50)
Coronary angiography 151 (55%) 12 (6%) 4.76 (3.22 – 7.14)
Coronary angioplasty 74 (27%) 30 (15%) 1.92 (1.28 – 2.94)
Coronary artery bypass grafting 66 (24%) 30 (15%) 1.75 (1.15 – 2.70)
* See text for eligibility criteriaBMC Cardiovascular Disorders 2004, 4:14 http://www.biomedcentral.com/1471-2261/4/14
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between type of physician and survival or are known to be
associated with survival and were not comparable
between the two groups.
Eligibility criteria for appropriate use of effective medi-
cines [13].
Thrombolytic therapy
• No warfarin therapy on admission
• ST-segment elevation on initial ECG
• Less than 12 hours since onset of chest pain
• Systolic BP less than 180 mmHg and diastolic BP less
than 110 mmHg at presentation
• No severe CVA, gastrointestinal disease or chronic liver
disease
Aspirin
• No haemorrhagic complication
• No severe CVA, gastrointestinal disease or chronic liver
disease or renal failure
• No warfarin therapy on admission
β blockers
• No chronic lung disease
• No cardiogenic shock, hypotension, complete heart
block or decompensated heart failure
The characteristics of the two hospitals are summarised
figure 1. The results from the two hospitals were com-
bined in order to make our findings more generalisable.
The general characteristics did not show important differ-
ences in the organisation of care between the hospitals. It
is unlikely there are important unmeasurable factors asso-
ciated with a particular hospital that might cause con-
founding, but hospital of care is still included as a variable
in the multivariate analysis to control for centre effect.
Patients from the two hospitals undergo procedures in the
same specialist cardiothoracic hospital.
The main outcome was eighteen-month survival defined
as time between date of AMI and death.
Statistical analysis was carried out using Stata (Version
6.0).
In general for Cox regression analysis, the number of
events i.e. deaths (and similarly the number of non-
events) per variable modelled should be at least 10 [12].
Ethical approval was obtained from the two local research
ethics committees of the hospitals involved in the study.
Permission from the director of research and Caldicott
guardians of data in each hospital was also obtained.
Results
Medical records were obtained for 94% of eligible patients
(476 of 506 patients). Four patients did not have enzyme
changes of myocardial infarction or were clear cases of
miscoding. The mean age of the cohort was 69.3 years (SD
13.2) and 34.5% were female. The patients with missing
records did not differ from those with records in terms of
age or sex using information from routine data (mean age
was 70.4 years with SD 11.1; 36.2% were female). There
were no significant differences in the proportion of data
missing between the two hospitals including those for eli-
gibility to effective medications and co morbidities.
General characteristics
Patients in our sample seen by a cardiologist were
younger, with a higher proportion of males to females.
They were more likely to have a history of CHD prior to
myocardial infarction, but less likely to have a history of
congestive heart failure or hypertension (Table 1).
Patients with impaired mobility or who smoked were less
likely to be seen by a cardiologist. The difference in the
proportion of patients with echocardiographic evidence
of impaired left ventricular function complicating their
myocardial infarction by physician seen was not
significant.
Drug and procedure use
The likelihood of receiving effective medication (throm-
bolytic therapy, β blockers, aspirin) was higher among
patients seen by a cardiologist compared with those not
seen by a cardiologist. Furthermore, patients seen by a car-
diologist were more likely to have undergone exercise test-
ing, angiography and revascularisation procedures (Table
2). The use of ACE inhibitors was not more frequent
among cardiologists.
Survival
Univariate analysis indicated that patients seen by a cardi-
ologist had better survival (hazard ratio 0.16, 95% CI 0.10
to 0.25).
Effect of seeing a cardiologist after controlling for patient 
characteristics
The survival of patients seen by a cardiologist was still bet-
ter than that for those not seen by a cardiologist (hazard
ratio 0.22, 95% CI 0.14 to 0.25) after controlling for theBMC Cardiovascular Disorders 2004, 4:14 http://www.biomedcentral.com/1471-2261/4/14
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confounding effect of pre-existing comorbidity, age, sex,
hospital first seen, deprivation and distance (Table 3). The
effect of seeing a cardiologist remained after excluding
patients that died within a week of MI. The hazard ratio
was 0.21 (95% CI 0.12 – 0.37).
Characteristics of study hospitals Figure 1
Characteristics of study hospitals.
Hospital 1  Hospital 2 
Number of cardiologist
(perform angiography)
6 (4)*  2(2)
AMI case load per year 257 patients 249 patients
Guidelines for AMI 
management
Yes Yes
Junior doctors Senior house officers and 
registrars
Senior house officers and 
registrars
Catchment population Approximately 400,000 Approximately 280,000
Policy on cardiologist
managing AMI 
To see all patients  To see all patients 
Follow up by cardiologist  Yes Yes
Coronary Care Unit  6 beds  8 beds 
Admission route  Via GPs, A & E, 
paramedical crew, 
directly to CCU
Via GPs, A&E, Medical 
Admissions Ward, 
general wards, 
paramedics
Other beds for step down 24 beds  15  beds
Use of cardiac enzymes
and markers of
myocardial necrosis 
Yes, including troponin T  Yes, including troponin T 
Policy on exercise testing  All patients before 
discharge except if 
contraindicated
All patients 3 weeks after
MI
Policy on 
echocardiography
All patients All patients 
Policy on angiography Access to all eligible Access to all eligible
Cardiac rehabilitation Yes offered Yes offered
GP – general practitioners 
A & E – accident and emergency department
AMI – Acute Myocardial Infarction 
*Includes academic staffBMC Cardiovascular Disorders 2004, 4:14 http://www.biomedcentral.com/1471-2261/4/14
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Effect of seeing a cardiologist after controlling for patient 
characteristics and use of effective intervention
The effect of seeing a cardiologist on survival became non-
significant once access to angiography, revascularisation
procedures and effective medicines (aspirin and/or β
blockers and/or thrombolysis) had been adjusted for. The
hazard ratio was 0.70 (95% CI 0.33 – 1.46). The fully
adjusted model indicated that the most important factor
affecting survival was access to effective medication.
(Table 3).
Discussion
This study improves our understanding of the care of AMI
by cardiologists and general physicians in UK hospitals.
Access to a cardiologist was univariately associated with
better survival. This effect remained after controlling for
the effect of patient characteristics, including the presence
of comorbidity, but disappeared when the confounding
effect of access to effective medicines was controlled for.
As noted in the analysis, patients seen by a cardiologist
were more likely to have been prescribed these medicines
and to have had exercise testing, angiography and revascu-
larisation. This implies that the survival advantage associ-
ated with being seen by a cardiologist is due to the more
frequent use of effective medicines and is similar to find-
ings by Chen J et al in the United States [3].
Previous studies have shown a high level of miscoding in
routine data for AMI patients (RM Norris cited in [2]). The
use of a case note review improved the findings of this
study by assisting in ascertaining the diagnosis of myocar-
dial infarction and ensuring the accuracy and complete-
ness of the data used in the analysis. The possibility
remains that some cases not seen through the cardiology
department and not recorded in the patient administra-
tion system were missed. This is likely to be a small
number and unlikely to invalidate the findings. Identify-
ing all patients with infarction is a major shortcoming of
many studies that estimate mortality among patients seen
by cardiologists [2]. This study includes all patients
irrespective of where they were managed in the hospital;
however patients dying from myocardial infarction before
arriving at the hospital were not included.
All cases diagnosed by the managing clinician as AMI with
ECG changes and found to have enzyme changes indicat-
ing myocardial necrosis were included in the analysis after
the case notes were reviewed. This may have involved
some misclassification due to misdiagnosis, but this is
likely to occur at random, affecting only a small number
of cases, and can only underestimate the effect of each
factor.
Limitations of this study include potential for bias in the
allocation of patients to treatments and physicians (ie car-
diologist/non cardiologist) that were not measured.
Another possible limitation is bias arising from medical
case notes which were unobtainable. Records from rou-
Table 3: Cox regression analysis for eighteen month survival comparing cardiologists and non-cardiologist physicians and controlling for 
potential confounders.
Variable Mortality (%) Adjusted hazard ratio (CI) * Adjusted hazard ratio (CI) #
Seen by a Cardiologist Yes 30 (11%) 0.22 (0.14 – 0.38) 0.70 (0.33 – 1.46)
No 88 (44%)
Comorbidity Yes 15 (25%) 1.11 (0.62 – 1.99) 0.98 (0.49 – 1.98)
No 107 (26%)
Hospital A 58 (24%) 1.01 (0.67 – 1.51) 1.08 (0.71 – 1.73)
B6 5  ( 2 8 % )
Age (years) 30 – 40 1 (8%) 1.05 (1.03 – 1.08) 1.03 (0.99 – 1.06)
41 – 60 8 (7%)
61 – 70 18 (17%)
71 – 99 96 (40%)
Sex Males 64 (21%) 0.91 (0.62 – 1.35) 0.83 (0.44 – 1.55)
Females 58 (34%)
Distance 1.0 (0.97 – 1.04) 0.96 (0.88 – 1.03)
Angiography Yes 12 (7%) - 0.87 (0.24 – 3.17)
No 112 (36%)
Revascularisation Yes 14 (13%) - 0.25 (0.04 – 1.52)
No 110 (30%)
Effective medicinesγ Yes 48 (14%) - 0.15 (0.07 – 0.29)
No 76 (56%)
* Adjusted for patient characteristics, hospital # Adjusted for patient characteristics, hospital and the use of effective medicines and procedures γ Access to 
aspirin, and/or β blockers and/ or thrombolysis if appropriateBMC Cardiovascular Disorders 2004, 4:14 http://www.biomedcentral.com/1471-2261/4/14
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tine data were used to examine whether those with miss-
ing records differed in any systematic way from those with
available records; it was found that they did not differ in
age or sex. The study did not use any criteria for judging
clinical appropriateness of the procedures used. Incom-
plete recording of information in the case notes hampered
the determination of appropriateness for effective medica-
tion. However there was no difference in the proportion
of missing data between the two hospitals.
Since doctors may selectively be referring younger patients
with lower comorbidity to a cardiologist, we controlled
for age and comorbidity in the analysis. However, residual
confounding from age and comorbidity could still
account for some of the observed difference in survival.
All patients admitted to the Coronary Care Unit (CCU) in
one of the hospitals are seen by a cardiologist and have a
higher chance of accessing thrombolysis, angiography
and revascularisation. A cardiologist also sees the majority
of patients admitted to the CCU in the second hospital.
The protocol for the management of AMI in both hospi-
tals stipulates a cardiology review of all AMI patients.
Access to a cardiologist may be a proxy measure of access
to effective treatment and it may not be the trigger for
effective treatment. These limitations mean that the find-
ings should be interpreted with a degree of caution. In
addition our inability to use formal appropriateness crite-
ria limits the interpretation of findings.
Despite these limitations the results indicate that, in the
short term, acute trusts can improve survival of patients by
increasing the use of effective medicines among general
physicians.
Conclusions
We observed better survival among patients seen by a car-
diologist compared with patients with no access to a car-
diologist, among a cohort of patients already admitted
with AMI. This effect was entirely explained by the more
frequent use of effective medicines by cardiologists in the
multivariate analysis. About eight hospitals in the UK
Royal College of Physicians survey have no cardiologist
and another 30% have a single cardiologist [2]. It will take
time to provide the minimum of two cardiologists per
hospital as recommended in the CHD NSF. There are sev-
eral reasons why a hospital may benefit from appointing
a cardiologist, ranging from the treatment of a specific
subgroup of patients that will benefit from revascularisa-
tion to prompt management of angina patients via rapid
access chest clinics. However, in the short term hospitals
can improve the survival of patients admitted with AMI by
improving access to effective medicines. Coordination of
care between cardiologists and general physicians and tar-
geted interventions using feedback from audit, research
and peer education are likely to lead to more frequent use
of effective cardiovascular medicines by general
physicians.
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